Santhera Pharmaceuticals Gains EU Boost for AGAMREE Expansion
PRATTELN, Switzerland, April 27, 2026 Santhera Pharmaceuticals has achieved a significant regulatory milestone with the European Medicines Agency’s (EMA)...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
PRATTELN, Switzerland, April 27, 2026 Santhera Pharmaceuticals has achieved a significant regulatory milestone with the European Medicines Agency’s (EMA)...
